Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Enrollment opened in phase 2 trial of DNA vaccine against cytomegalovirus
February 27th, 2006
Vical Incorporated (VICL) announced that enrollment has opened in its phase 2 trial of a DNA vaccine against cytomegalovirus (CMV). The phase 2 trial will be conducted at U.S. transplant centers in donors and patients undergoing stem cell transplants Success in this patient population would support Vical's expansion of studies of its CMV vaccine into other transplant settings and the general population. CMV is a herpes virus that infects more than half of all adults in the United States by age 40, and is even more widespread in developing countries. While a healthy immune system typically protects an infected person against CMV disease, it rarely...
Source: Pharma Business Week (2006-02-27)
|
